NCALD as a potential predictive biomarker for the efficacy of platinum-based chemotherapy in ovarian cancer

Sarah M. Konrad, Kristina Schwamborn, Achim Krüger, Katja Honert, Manfred Schmitt, Daniela Hellmann, Barbara Schmalfeldt, Alfons Meindl, Marion Kiechle, Anne S. Quante, Christine Brambs, Sabine Grill, Juliane Ramser

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: Since reliable response predictors to platinum-based chemotherapy in ovarian cancer (OC) are scarce, we characterize NCALD as a predictive biomarker. Materials & methods: NCALD mRNA (n = 100) and protein (n = 102) expression was analyzed in OC samples and associated with patient outcome. A stable OC cell line knockdown was generated and cellular response to platinum was explored. Results: High NCALD mRNA and protein expression was significantly associated with longer overall patient survival (p = 0.037/0.002). Knockdown experiments revealed a significant association between cisplatin sensitivity and NCALD expression. Conclusion: Low NCALD expression was associated with reduced sensitivity to platinum-based chemotherapy. NCALD may be a new biomarker candidate to identify patients who might benefit from platinum-based chemotherapy.

Original languageEnglish
Pages (from-to)1029-1041
Number of pages13
JournalBiomarkers in Medicine
Volume16
Issue number14
DOIs
StatePublished - 29 Nov 2022

Keywords

  • NCALD
  • ovarian cancer
  • platinum
  • platinum sensitivity
  • predictive biomarker
  • prognosis

Fingerprint

Dive into the research topics of 'NCALD as a potential predictive biomarker for the efficacy of platinum-based chemotherapy in ovarian cancer'. Together they form a unique fingerprint.

Cite this